A framework to mitigate the risk of chemical leukoderma: Consumer products.

[1]  S. Ito,et al.  Rhododendrol‐induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism‐based treatments in comparison with vitiligo , 2021, The Journal of dermatology.

[2]  S. Ito,et al.  Rhododendrol‐induced leukoderma update I: Clinical findings and treatment , 2021, The Journal of dermatology.

[3]  K. Wakamatsu,et al.  Chemical Reactivities of ortho-Quinones Produced in Living Organisms: Fate of Quinonoid Products Formed by Tyrosinase and Phenoloxidase Action on Phenols and Catechols , 2020, International journal of molecular sciences.

[4]  Tamio Suzuki,et al.  Expression of discoidin domain receptor 1 and E‐cadherin in epidermis affects melanocyte behavior in rhododendrol‐induced leukoderma mouse model , 2020, The Journal of dermatology.

[5]  H. Nagai,et al.  Genome‐wide association study identifies CDH13 as a susceptibility gene for rhododendrol‐induced leukoderma , 2020, Pigment cell & melanoma research.

[6]  G. A. Burton,et al.  RIFM fragrance ingredient safety assessment, 4-(p-hydroxyphenyl)-2-butanone, CAS Registry Number 5471-51-2. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[7]  N. Ohgami,et al.  A unique system that can sensitively assess the risk of chemical leukoderma by using murine tail skin. , 2019, Chemosphere.

[8]  K. Wakamatsu,et al.  Tyrosinase‐catalyzed oxidation of resveratrol produces a highly reactive ortho‐quinone: Implications for melanocyte toxicity , 2019, Pigment cell & melanoma research.

[9]  M. Picardo,et al.  Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions. , 2019, Journal of the American Academy of Dermatology.

[10]  T. Slaga,et al.  Safety Assessment of Tocopherols and Tocotrienols as Used in Cosmetics , 2018, International journal of toxicology.

[11]  D. Sheffield,et al.  A study of inter-individual variability in the Phase II metabolism of xenobiotics in human skin. , 2018, Toxicology letters.

[12]  K. Wakamatsu,et al.  Biochemical Mechanism of Rhododendrol-Induced Leukoderma , 2018, International journal of molecular sciences.

[13]  V. Isaac,et al.  Caffeic Acid in Dermatological Formulations: In Vitro Release Profile and Skin Absorption. , 2017, Combinatorial chemistry & high throughput screening.

[14]  Haifeng Zeng,et al.  In Vitro Methods for Predicting Chemical Leukoderma Caused by Quasi-Drug Cosmetics , 2017 .

[15]  T. Slaga,et al.  Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics , 2017, International journal of toxicology.

[16]  K. Wakamatsu,et al.  Tyrosinase-Catalyzed Oxidation of the Leukoderma-Inducing Agent Raspberry Ketone Produces (E)-4-(3-Oxo-1-butenyl)-1,2-benzoquinone: Implications for Melanocyte Toxicity. , 2017, Chemical research in toxicology.

[17]  K. Wakamatsu,et al.  The potent pro‐oxidant activity of rhododendrol–eumelanin induces cysteine depletion in B16 melanoma cells , 2017, Pigment cell & melanoma research.

[18]  Takumi Akiyama,et al.  Risk assessment of skin lightening cosmetics containing hydroquinone. , 2016, Regulatory toxicology and pharmacology : RTP.

[19]  T. Kunisada,et al.  A mouse model of leukoderma induced by rhododendrol , 2016 .

[20]  Fabian P. Steinmetz,et al.  Linking existing in vitro dermal absorption data to physicochemical properties: Contribution to the design of a weight-of-evidence approach for the safety evaluation of cosmetic ingredients with low dermal bioavailability. , 2016, Regulatory toxicology and pharmacology : RTP.

[21]  K. Wakamatsu,et al.  A convenient screening method to differentiate phenolic skin whitening tyrosinase inhibitors from leukoderma-inducing phenols. , 2015, Journal of dermatological science.

[22]  J. Viña,et al.  Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans , 2015, Oxidative medicine and cellular longevity.

[23]  Klaus Fischer,et al.  Oxidative transformation processes and products of para-phenylenediamine (PPD) and para-toluenediamine (PTD)—a review , 2015, Environmental Sciences Europe.

[24]  K. Wakamatsu,et al.  Tyrosinase‐catalyzed metabolism of rhododendrol (RD) in B16 melanoma cells: production of RD‐pheomelanin and covalent binding with thiol proteins , 2015, Pigment cell & melanoma research.

[25]  M. Yamakawa,et al.  An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients. , 2015, Journal of dermatological science.

[26]  Y. Tokura,et al.  Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma. , 2015, Journal of dermatological science.

[27]  M. Wataya-Kaneda,et al.  4-(4-hydroroxyphenyl)-2-butanol (rhododendrol) activates the autophagy-lysosome pathway in melanocytes: insights into the mechanisms of rhododendrol-induced leukoderma. , 2015, Journal of dermatological science.

[28]  T. Yamashita,et al.  Guide for medical professionals (i.e. dermatologists) for the management of Rhododenol‐induced leukoderma , 2015, The Journal of dermatology.

[29]  M. Yanagida,et al.  Metabolism of Skin-Absorbed Resveratrol into Its Glucuronized Form in Mouse Skin , 2014, PloS one.

[30]  A. Hachiya,et al.  Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold. , 2014, Journal of dermatological science.

[31]  Tamio Suzuki,et al.  Rhododendrol, a depigmentation‐inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase‐dependent mechanism , 2014, Pigment cell & melanoma research.

[32]  Tamio Suzuki,et al.  Depigmentation of the skin induced by 4-(4-hydroxyphenyl)-2-butanol is spontaneously re-pigmented in brown and black guinea pigs. , 2014, The Journal of toxicological sciences.

[33]  S. Kim,et al.  Inhibitory Effects of Resveratrol on Melanin Synthesis in Ultraviolet B-Induced Pigmentation in Guinea Pig Skin , 2014, Biomolecules & therapeutics.

[34]  Joan Eilstein,et al.  Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  J. Estrela,et al.  Pterostilbene: Biomedical applications , 2013, Critical reviews in clinical laboratory sciences.

[36]  F. Clubb,et al.  Swine as Models in Biomedical Research and Toxicology Testing , 2012, Veterinary pathology.

[37]  H. Ding,et al.  Evaluation of in Vitro and in Vivo Depigmenting Activity of Raspberry Ketone from Rheum officinale , 2011, International journal of molecular sciences.

[38]  S. Ghosh.  CHEMICAL LEUKODERMA: WHAT’S NEW ON ETIOPATHOLOGICAL AND CLINICAL ASPECTS? , 2010, Indian Journal of Dermatology.

[39]  Karen Blackburn,et al.  A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. , 2010, Regulatory toxicology and pharmacology : RTP.

[40]  Fernand Labrie,et al.  Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin™ and full thickness model from Episkin™ , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  G. Burdock,et al.  Safety studies conducted on high-purity trans-resveratrol in experimental animals. , 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[42]  S. Ghosh,et al.  Chemical leucoderma: a clinico‐aetiological study of 864 cases in the perspective of a developing country , 2009, The British journal of dermatology.

[43]  J. P. Mestres,et al.  The "in vitro" percutaneous penetration of three antioxidant compounds. , 2007, International journal of pharmaceutics.

[44]  H. Takiwaki,et al.  Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible , 2005, Experimental dermatology.

[45]  Jin-Lan Zhang,et al.  Metabolism of ferulic acid in rats , 2005, Journal of Asian natural products research.

[46]  R. Boissy,et al.  On the etiology of contact/occupational vitiligo. , 2004, Pigment cell research.

[47]  J. Pezzuto,et al.  Human, Rat, and Mouse Metabolism of Resveratrol , 2002, Pharmaceutical Research.

[48]  G. Hillebrand,et al.  The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer , 2002, The British journal of dermatology.

[49]  L. Rondini,et al.  Sulfated ferulic acid is the main in vivo metabolite found after short-term ingestion of free ferulic acid in rats. , 2002, Journal of agricultural and food chemistry.

[50]  D. Paolino,et al.  In vitro and in vivo evaluation of caffeic and ferulic acids as topical photoprotective agents. , 2000, International journal of pharmaceutics.

[51]  J. Bolton,et al.  Role of quinones in toxicology. , 2000, Chemical research in toxicology.

[52]  A. DeCaprio.  The toxicology of hydroquinone--relevance to occupational and environmental exposure. , 1999, Critical reviews in toxicology.

[53]  M. Nagano,et al.  Occupational Leukoderma in Workers Engaged in 4‐(p‐Hydroxyphenyl)‐2‐Butanone Manufacturing , 1998 .

[54]  M. Nagano,et al.  An Experimental Study on Depigmenting Activity of 4‐(p‐Hydroxyphenyl)‐2‐Butanone in C57 Black Mice , 1998 .

[55]  E. Graf,et al.  Antioxidant potential of ferulic acid. , 1992, Free radical biology & medicine.

[56]  A. Fisher.  Can bleaching creams containing 2% hydroquinone produce leukoderma? , 1982, Journal of the American Academy of Dermatology.

[57]  R. Scheline,et al.  The metabolism of 4-(4-hydroxyphenyl)butan-2-one (raspberry ketone) in rats, guinea-pigs and rabbits. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.

[58]  H. Maibach,et al.  Perioral leukoderma simulating vitiligo from use of a toothpaste containing cinnamic aldehyde. , 1980, Archives of dermatology.

[59]  M. Misiaszek,et al.  Detection of environmental depigmenting substances , 1979, Contact dermatitis.

[60]  T. Fitzpatrick,et al.  Mechanism of depigmentation by hydroquinone. , 1974, The Journal of investigative dermatology.

[61]  L. Schwartz,et al.  Occupational Leukoderma. Preliminary Report. , 1939 .

[62]  C. Foti,et al.  Chemical Leukoderma. , 2016, Dermatitis : contact, atopic, occupational, drug.

[63]  K. Kilgore,et al.  Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. , 1994, Skin pharmacology : the official journal of the Skin Pharmacology Society.